MedTrace Logo

TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia

NCT03136445 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 616

Last updated 2025-10-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to test whether giving tranexamic acid to patients receiving treatment for blood cancers reduces the risk of bleeding or death, and the need for platelet transfusions. Patients will be randomised to receive tranexamic acid (given intravenously through a drip, or orally) or a placebo.

Conditions

  • Hematologic Neoplasms
  • Hemorrhage
  • Hematopoietic Stem Cell Transplantation

Interventions

DRUG

Tranexamic acid (TXA).

IV or oral preparation. IV tranexamic acid or Oral tablet of tranexamic acid.

DRUG

Placebo

IV (saline) or oral placebo tablets

Sponsors & Collaborators

  • National Health and Medical Research Council, Australia

    collaborator OTHER

  • Monash University

    collaborator OTHER

  • NHS Blood and Transplant

    lead OTHER_GOV

Principal Investigators

  • Lise J Estcourt, MBBChir MSc DPhil MRCP FRCPath · NHS Blood and Transplant

  • Zoe K McQuilten, MBBS PhD · Monash University

  • Simon J Stanworth, DPhil FRCP FRCPath · NHS Blood and Transplant

  • Erica M Wood, MB BS, FRACP, FRCPA · Monash University

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-30
Primary Completion
2022-02-18
Completion
2022-06-18

Countries

  • Australia
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03136445 on ClinicalTrials.gov